Clinical Trial: A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patien

Brief Summary: The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).

Detailed Summary: The duration of treatment is 4 months.
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Plasma LDL-C

Original Primary Outcome:

Current Secondary Outcome: Plasma LDL-C, TG and HDL-C. The proportion of patients achieving LDL-C targets. Tolerability.

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: September 23, 2004
Date Started: September 2002
Date Completion:
Last Updated: March 9, 2017
Last Verified: March 2017